How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years.

Stéphane EpelbaumClaire PaquetJacques HugonJulien DumurgierDavid WallonDidier HannequinThérèse JonveauxAnnick BesozziStéphane PouponneauCaroline HommetFrederic BlancLaetitia BerlyAdrien JulianMarc PaccalinFlorence PasquierJulie BelletClaire Boutoleau-BretonniereThiphaine CharriauOlivier RouaudOlivier MadecAurélie MoutonRenaud DavidSamir BekadarRoxane FabreEmmanuelle LiegeyWalter DeberdtPhilippe RobertBruno Dubois

Published in: BMJ open (2019)

AD was not frequently diagnosed at a prodromal or mild dementia stage in France in 2014 to 2018. Diagnosis rarely relied on a pathophysiological marker even in expert memory centres. National databases will be valuable to monitor early stage AD diagnosis efficacy in memory centres when a disease-modifying treatment becomes available.

Keyphrases

early stage
end stage renal disease
ejection fraction
working memory
quality improvement
chronic kidney disease
newly diagnosed
mild cognitive impairment
peritoneal dialysis
radiation therapy
machine learning
combination therapy
clinical practice
cognitive impairment
artificial intelligence